Aethlon Medical (AEMD) Emerging Growth Virtual Conference summary

Product overview and clinical focus

• Hemopurifier is an extracorporeal device designed to remove infectious viruses and cancer-related extracellular vesicles from the bloodstream, compatible with standard hospital blood-pumping equipment.

• Initially developed for viral infections, the main focus has shifted to oncology, specifically targeting patients with solid tumors unresponsive to anti-PD-1 therapies.

• The device has treated 44 patients in 173 sessions, showing a favorable safety profile with only minor side effects and procedural improvements over time.

• The current trial is a three-cohort, dose-escalation study in solid tumor patients, with the first two cohorts completed and awaiting Data Safety Monitoring Board review for the third.

• Key trial milestones include safety board meetings, central lab data on vesicle removal and T-cell improvement, and final cohort completion.

Operational strategy and trial execution

• Trials are conducted in Australia due to high-quality medical infrastructure and a 43% cash rebate on clinical expenditures, significantly reducing costs.

• Data from Australian trials are accepted by the FDA, and the company holds Breakthrough Device designations for both viral and oncology indications.

• Recruitment has accelerated through partnerships with online patient outreach and screening platforms, resulting in a pipeline of pre-qualified candidates for upcoming cohorts.

• The company is maintaining strong engagement with trial sites and patients, ensuring readiness for rapid enrollment once regulatory approvals are received.

Technology evolution and market positioning

• The SLAM platform aims to simplify treatment by enabling use with a thinner catheter and portable blood pump, allowing procedures outside dialysis units and improving patient comfort.

• Early studies are underway to confirm compatibility with the SLAM system, potentially expanding the addressable market and treatment settings.

• The approach is differentiated from drugs and vaccines by physically removing extracellular vesicles, potentially offering a cleaner safety profile.

• The target market includes patients who do not respond to leading immunotherapies, representing a significant unmet need within the multi-billion dollar oncology sector.